Overview

Biosimulation Market Introduction:

Biosimulation Market is predicted to value over USD 4 billion by 2027 end with a CAGR of over 15% during the forecast period 2020 to 2027.

Bio-simulation is a distinct part of systems biology, which gives information about complex biological systems in disease and health. The bio-simulation is also referred to as in-silico biology, which means biological experiments have to carry out in the computer. It is an entirely new concept in the drug development industry, which relies on expressing the biological systems with mathematical expressions, thus, capturing biological elements and their relationships, and simulating the behaviour of certain systems in different situations. There are different types of bio-simulation approaches are available which gives outcome based on the complexity of biosystem and the disease- drug target. It credits the reduction and replacement of animal and human experimentations as well as improves the knowledge of how patients need to administer medicine.

Biosimulation has a huge demand for drug development for mimicking disease indication. It is used to simulate the disease indication and decrease the effort of research. Increasing attrition rates of drug development have increased the dependence of research companies on simulation techniques for minimizing capital investments. Additionally, the rapid advancement of technologies has integrated the biosimulation process in clinical trials and offers complete automation. Biosimulation techniques also minimize human errors and increase the efficiency of the development process. Further, it also decreases the development time and speeds up the whole drug discovery process. All these factors led to robust growth of the market during the forecast period. Global Biosimulation market is expected to witness a high adoption rate due to increasing awareness of simulation techniques among the drug developing companies.

North America market is expected to account major share in the global market due to high R&D investments of top drug manufacturers. It was followed by the European region and it also accounts significant share over the forecast period. It is expected to witness high growth rate over the forecast period. Both North America and Europe market is expected to remain dominant in the global market over the forecast period. The Asia Pacific, Latin America and Rest of the world market are expected to account a small fraction of market share due to less adoption.

Biosimulation market players include
Certara, Simulations Plus, Dassault Systèmes, Schrödinger, ACD/Labs, Chemical Computing Group, Physiomics, Evidera, In silico biosciences, INOSIM Software, Insilico Biotechnology, LeadInvent Technologies, Rosa, Nuventra Pharma , and Genedata.

                                                       
Biosimulation Market Segmentation:

By Product & Service

• Software
• Molecular Modeling and Simulation Software
• PBPK Modeling and Simulation Software
• PK/PD Modeling and Simulation Software
• Trial Design Software
• Toxicity Prediction Software
• Other Biosimulation Software
• Services
• In-house Services
• Contract Services

By Application

• Drug Development
• Drug Discovery    
• Other Applications              

By Delivery Model

• Subscription Models
• Ownership Models

By End User

• Pharmaceutical and Biotechnology Companies
• Research Institutes
• Contract Research Organizations
• Regulatory Authorities
• Other End Users

By Region  

• Europe  
• North America  
• APAC  
• Latin America 
• Rest of World 

Competitive Landscape: 

• Tier 1 players- established companies in the market with a major market share  
• Tier 2 players 
• Emerging players which are growing rapidly 
• New Entrants   

 FutureWise Takeaways:  

• Growth prospects  
• SWOT analysis 
• Key trends 
• Key data-points affecting market growth

Objectives of the Study:

• To provide with an exhaustive analysis on the global market by product & service, by application, by delivery model, by end user and by region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) 
• To evaluate and forecast micro-markets and the overall market  
• To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East 
• To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
• Profiling of companies to evaluate their market shares, strategies, financials and core competencies 

Flexible Delivery Model:

•    We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
•    The customization Mobility Care offered are free of charge with purchase of any license of the report
•    You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
         1.1 Objectives of the Study 
         1.2 Market Definition 
         1.3 Market Scope 
               1.3.1. Years Considered for the Study
               1.3.2. Market Covered
         1.4 Currency   
         1.5 Limitations 
         1.6 Stakeholders 
 2. Research Methodology 
         2.1 Research Data 
                 2.1.1 Secondary Data
                           2.1.1.1 Key Data From Secondary Sources
                 2.1.2 Primary Data
                           2.1.2.1 Key Data From Primary Sources
        2.2 Market Size Estimation 
        2.3 Market Breakdown and Data Triangulation 
        2.4 Assumptions for the Study
3. Executive Summary
        3.1 Market Outlook
        3.2 Segment Outlook
        3.3 Competitive Insights
4. Global Biosimulation Market Variables, Trends & Scope
       4.1. Market Lineage Outlook
       4.2. Penetration and Growth Prospect Mapping
       4.3. Industry Value Chain Analysis
       4.4. Cost Analysis Breakdown
       4.5. Technology Overview
       4.6. Regulatory Framework
                 4.6.1. Reimbursement Framework
                 4.6.2. Standards And Compliances
5. Market Overview
         5.1. Market Dynamics
                  5.1.1. Market Driver Analysis
                            5.1.1.1. Increasing focus on Brand Protection
                            5.1.1.2. Untapped Opportunities in Emerging Regions
                  5.1.2. Market Restraint Analysis
                  5.1.3. Industry Challenges
                            5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Global Biosimulation Market Analysis Tools
         6.1. Industry Analysis - Porter’s
               6.1.1. Supplier Power
               6.1.2. Buyer Power
               6.1.3. Substitution Threat
               6.1.4. Threat from New Entrants
               6.1.5. Competitive Rivalry
         6.2. Pestel Analysis
               6.2.1. Political Landscape
               6.2.2. Environmental Landscape
               6.2.3. Social Landscape
               6.2.4. Technology Landscape
               6.2.5. Legal Landscape
         6.3. Major Deals And Strategic Alliances Analysis
                6.3.1. Joint Ventures
                6.3.2. Mergers and Acquisitions
                6.3.3. Licensing and Partnership
                6.3.4. Technology Collaborations
                6.3.5. Strategic Divestments
         6.4. Market Entry Strategies
         6.5. Case Studies
7. Global Biosimulation Market, By Product & Services Type Historical Analysis and Forecast 2020-2027 (USD Million)
           7.1. Software
                   7.1.1. Molecular Modeling and Simulation Software
                   7.1.2. PBPK Modeling and Simulation Software
                   7.1.3. PK/PD Modeling and Simulation Software
                   7.1.4. Trial Design Software
                   7.1.5. Toxicity Prediction Software
                   7.1.6. Other Biosimulation Software
           7.2. Services
                   7.2.1. In-house Services
                   7.2.2. Contract Services
8. Global Biosimulation Market, By Application Historical Analysis and Forecast 2020-2027 (USD Million)
           8.1. Drug Development
           8.2. Drug Discovery
           8.3. Other Applications
9. Global Biosimulation Market, By End User Historical Analysis and Forecast 2020-2027 (USD Million)
           9.1. Biopharmaceutical Companies
           9.2. Contract Research Organization
           9.3. Academic Institutes
10.  North America Biosimulation Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) along with expected regulatory needs
     10.1. Introduction
     10.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
            10.2.1. U.S.A
            10.2.2. Canada
            10.2.3. Mexico
     10.3. Market Size (USD Million) Forecast for North America 2020-2027
11. Europe Biosimulation Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
     11.1. Introduction
     11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
           11.2.1. Germany
           11.2.2. U.K
           11.2.3. France
           11.2.4. Italy
           11.2.5. Spain
           11.2.6. Russia
           11.2.7. Poland
           11.2.8. Switzerland
           11.2.9. Rest of Western Europe
12. Asia Pacific Biosimulation Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) - along with expected regulatory needs
        12.1. Introduction
        12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 
             12.2.1. Japan
             12.2.2. China
             12.2.3. Singapore
             12.2.4. India
             12.2.5. Australia and New Zealand
             12.2.6. ASEAN
             12.2.7. South Korea
             12.2.8. Rest of Asia Pacific
        12.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027
13. Latin America Biosimulation Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 
         13.1. Introduction
         13.2. Regional Market Trends
         13.3. Historical Market Size (USD Million) Analysis By Country, 2015-2019
                  13.3.1. Brazil
                  13.3.2. Venezuela
                  13.3.3. Argentina
                  13.3.4. Rest of Latin America
         13.4. Market Size (USD Million) Forecast for Latin America 2020-2027
14. Rest of World Biosimulation Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
         14.1. Introduction
         14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
                  14.2.1. Saudi Arabia
                  14.2.2. UAE
                  14.2.3. South Africa
                  14.2.4. Egypt
         14.3. Market Size (USD Million) Forecast for MEA 2020-2027
15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts)
         15.1. Schrödinger
                15.1.1. Company Overview
                15.1.2. Product Portfolio
                15.1.3. SWOT Analysis
                15.1.4. Financial Overview
                15.1.5. Strategic Overview
         15.2. Simulation Plus
                15.2.1. Company Overview
                15.2.2. Product Portfolio
                15.2.3. SWOT Analysis
                15.2.4. Financial Overview
                15.2.5. Strategic Overview
         15.3. INOSIM Software Dassault Systèmes
                15.3.1. Company Overview
                15.3.2. Product Portfolio
                15.3.3. SWOT Analysis
                15.3.4. Financial Overview
                15.3.5. Strategic Overview
         15.4. LeadInvent Technologies
                15.4.1. Company Overview
                15.4.2. Product Portfolio
                15.4.3. SWOT Analysis
                15.4.4. Financial Overview
                15.4.5. Strategic Overview

         15.5. Schrödinger
                15.1.1. Company Overview
                15.1.2. Product Portfolio
                15.1.3. SWOT Analysis
                15.1.4. Financial Overview
                15.1.5. Strategic Overview
         15.6. Simulation Plus
                15.2.1. Company Overview
                15.2.2. Product Portfolio
                15.2.3. SWOT Analysis
                15.2.4. Financial Overview
                15.2.5. Strategic Overview
         15.7 INOSIM Software Dassault Systèmes
                15.3.1. Company Overview
                15.3.2. Product Portfolio
                15.3.3. SWOT Analysis
                15.3.4. Financial Overview
                15.3.5. Strategic Overview
         15.8. LeadInvent Technologies
                15.4.1. Company Overview
                15.4.2. Product Portfolio
                15.4.3. SWOT Analysis
                15.4.4. Financial Overview
                15.4.5. Strategic Overview
         15.9. Schrödinger
                15.1.1. Company Overview
                15.1.2. Product Portfolio
                15.1.3. SWOT Analysis
                15.1.4. Financial Overview
                15.1.5. Strategic Overview
         15.10. Simulation Plus
                15.2.1. Company Overview
                15.2.2. Product Portfolio
                15.2.3. SWOT Analysis
                15.2.4. Financial Overview
                15.2.5. Strategic Overview
         15.11. INOSIM Software Dassault Systèmes
                15.3.1. Company Overview
                15.3.2. Product Portfolio
                15.3.3. SWOT Analysis
                15.3.4. Financial Overview
                15.3.5. Strategic Overview
         15.12. LeadInvent Technologies
                15.4.1. Company Overview
                15.4.2. Product Portfolio
                15.4.3. SWOT Analysis
                15.4.4. Financial Overview
                15.4.5. Strategic Overview
         15.13. Schrödinger
                15.1.1. Company Overview
                15.1.2. Product Portfolio
                15.1.3. SWOT Analysis
                15.1.4. Financial Overview
                15.1.5. Strategic Overview
         15.14. Simulation Plus
                15.2.1. Company Overview
                15.2.2. Product Portfolio
                15.2.3. SWOT Analysis
                15.2.4. Financial Overview
                15.2.5. Strategic Overview
         15.15. INOSIM Software Dassault Systèmes
                15.3.1. Company Overview
                15.3.2. Product Portfolio
                15.3.3. SWOT Analysis
                15.3.4. Financial Overview
                15.3.5. Strategic Overview
16. FutureWise SME key takeaway points for Client

Tables

Figures